Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma.
http://cadciales.com/ - 20 mg cialis The age range of the patients was 14 to 71 years, and the glycated hemoglobin level ranged from 5.